Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene test may predict metformin success in PCOS

NCT ID NCT05680805

Knowledge-focused Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether certain gene variations influence how well the diabetes drug metformin works in women with polycystic ovary syndrome (PCOS). Researchers will give 100 women with PCOS metformin for 24 weeks and measure changes in insulin resistance, weight, and cholesterol. They will also check for specific gene variants to see if they predict who responds best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If successful, this could help doctors predict which PCOS patients will benefit most from metformin based on their genes.
What could go wrong
This is a small, early-phase study focused on genetic links, not a treatment trial. Results may not change clinical practice directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Newly diagnosed women of reproductive age (18 - 35 years) PCOS patients Exclusion Criteria: * • Patients having known similar endocrine disorders (hypothyroidism, hyperprolactinemia, androgen producing tumor, congenital adrenal hyperplasia, etc) * Planning to conceive within next six months, pregnant/ lactating mother * Patients with known diabetes mellitus, ischemic heart disease, chronic liver (serum ALT \>2 × upper limit of normal) and renal disease (eGFR \<60 ml/minute/1.73 m2 body surface area) * Patients taking oral contraceptive, steroid or drugs affecting insulin resistance (metformin, pioglitazone)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metformin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metformin Polycystic ovary syndrome

Contacts and locations

Locations

  • Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University

    Dhaka, 1000, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.